Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine

A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age

Persistence of antibodies and kinetics of B cell response in healthy children after vaccination with MCC vaccine

Inclusion Criteria:

• Healthy children

Exclusion Criteria:

• Known hypersensitivity to any vaccine products
• Any immunodeficiency, genetic anomaly or severe acute or chronic illness